
94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
ORIGINAL RESEARCH article
Front. Neurol. , 01 November 2022
Sec. Dementia and Neurodegenerative Diseases
Volume 13 - 2022 | https://doi.org/10.3389/fneur.2022.991143
This article is part of the Research Topic Advances in Integrative Medicine for Neurodegenerative Diseases: From Basic Research to Clinical Practice View all 11 articles
A retraction of this article was approved in:
Retraction: CSF p-tau as a potential cognition impairment biomarker in ALS
Citation: Gong Z, Gao L, Lu Y and Wang Z (2022) CSF p-tau as a potential cognition impairment biomarker in ALS. Front. Neurol. 13:991143. doi: 10.3389/fneur.2022.991143
Received: 11 July 2022; Accepted: 11 October 2022;
Published: 01 November 2022; Retracted: 04 March 2024.
Edited by:
Shaonan Liu, Guangdong Provincial Hospital of Chinese Medicine, ChinaReviewed by:
Antonio Giuliano Zippo, National Research Council (CNR), ItalyDisclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Research integrity at Frontiers
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.